Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
infant RSV monoclonal antibody
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular
01
Overview
Infant RSV monoclonal antibody refers to a class of passive immunization therapies designed to protect infants from respiratory syncytial virus (RSV) infection, the leading cause of bronchiolitis and pneumonia in children under 12 months. These long-acting monoclonal antibodies target the RSV fusion (F) protein to neutralize the virus and prevent host cell entry. In the context of the PIPELINE-RSV adaptive platform trial (sponsored by Fondazione Penta ETS), the specific infant RSV monoclonal antibody evaluated is nirsevimab (brand name: Beyfortus), developed by AstraZeneca and Sanofi. Another recently approved agent in this class is clesrovimab (brand name: Enflonsia), developed by Merck, while palivizumab (brand name: Synagis) has historically been used for high-risk infants.
- Other names
- infant RSV mAbinfant respiratory syncytial virus monoclonal antibody
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on infant RSV monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on infant RSV monoclonal antibody.